Trial · NCT01609556
Results by group283
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 283
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Dose-Escalation Phase: Maximum Tolerated Dose (MTD) of Mirvetuximab Soravtansine | Dose Escalation: Schedule A (Mirvetuximab Soravtansine Q3W) | 6.0 | mg/kg | ||
| Dose-Escalation Phase: Maximum Tolerated Dose (MTD) of Mirvetuximab Soravtansine | Dose Escalation: Schedule B (Mirvetuximab Soravtansine Weekly) | 2.0 | mg/kg | ||
| Dose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of Mirvetuximab Soravtansine | Dose Escalation: Schedule A (Mirvetuximab Soravtansine Q3W) | 6.0 | mg/kg | ||
| Number of Participants With TEAEs | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W) | Any TEAE | 2 | Participants | |
| Number of Participants With TEAEs | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W) | Any TEAE | 1 | Participants | |
| Number of Participants With TEAEs | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W) | Any TEAE | 0 | Participants | |
| Number of Participants With TEAEs | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W) | Any TEAE | 1 | Participants | |
| Number of Participants With TEAEs | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W) | Any TEAE | 9 | Participants | |
| Number of Participants With TEAEs | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W) | Any TEAE | 18 | Participants | |
| Number of Participants With TEAEs | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W) | Any TEAE | 7 | Participants | |
| Number of Participants With TEAEs | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W) | Any TEAE | 5 | Participants | |
| Number of Participants With TEAEs | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly) | Any TEAE | 5 | Participants | |
| Number of Participants With TEAEs | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly) | Any TEAE | 4 | Participants | |
| Number of Participants With TEAEs | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly) | Any TEAE | 9 | Participants | |
| Number of Participants With TEAEs | Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly) | Any TEAE | 7 | Participants | |
| Number of Participants With TEAEs | Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W) | Any TEAE | 46 | Participants | |
| Number of Participants With TEAEs | Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W) | Any TEAE | 24 | Participants | |
| Number of Participants With TEAEs | Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W) | Any TEAE | 27 | Participants | |
| Number of Participants With TEAEs | Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W) | Any TEAE | 40 | Participants | |
| Number of Participants With TEAEs | Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W) | SAEs | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01609556/results